
Blackstone Life Sciences, which is part of the Blackstone group, has entered a collaboration with French pharmaceutical firm Sanofi, according to a joint press release.
Blackstone will invest EUR 300m with the aim of getting Sanofi’s drug Sarclisa, a treatment of the type of bone marrow cancer known as multiple myeloma, on the market in a subcutaneous formulation, meaning the drug is administered under the skin.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app